Takeda Pharmaceutical (TAK) vs Vertex Pharmaceuticals (VRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Takeda Pharmaceutical (TAK) has outperformed Vertex Pharmaceuticals (VRTX) over the past year, gaining 27.0% versus a gain of 23.2%. Over five years, VRTX leads with a +178.2% price change compared with +30.3% for TAK. Vertex Pharmaceuticals is the larger company by market cap ($128.16 billion vs $58.68 billion), about 2.2 times the size.
On valuation, Vertex Pharmaceuticals trades at a lower forward P/E (25.1x vs 34.7x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 1088.73%, while Vertex Pharmaceuticals does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TAK | VRTX |
|---|---|---|
| Share price | $18.37 | $505.64 |
| Market cap | $58.68B | $128.16B |
| 1-day change | +1.49% | +0.66% |
| YTD return | +17.83% | +11.53% |
| 1-year return | +27.04% | +23.24% |
| 5-year return | +30.28% | +178.18% |
| P/E ratio (TTM) | — | 29.45 |
| Forward P/E | 34.66 | 25.15 |
| EPS (TTM) | $-0.34 | $17.17 |
| Dividend yield | 1088.73% | 0.00% |
| Annual dividend | $200.00 | $0.00 |
| Revenue (latest FY) | — | $12.00B |
| Revenue growth (YoY) | — | +8.90% |
| Net income (latest FY) | — | $3.95B |
| Gross margin | — | 86.24% |
| Operating margin | — | 34.77% |
| Net margin | — | 32.94% |
| 52-week high | $19.10 | $560.25 |
| 52-week low | $12.99 | $402.58 |
| Distance from 52-week high | -3.82% | -9.75% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +19.54% | +13.00% |
| Average volume | 3.03M | 1.16M |
| Shares outstanding | 3.19B | 253.46M |
| Employees | 47,029 | 6,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Vertex Pharmaceuticals is about 2.2 times larger than Takeda Pharmaceutical by market value ($128.16B vs $58.68B).
- Takeda Pharmaceutical offers a meaningfully higher dividend yield (1088.73% vs 0.00%).
About Takeda Pharmaceutical
TAK stock →Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees
About Vertex Pharmaceuticals
VRTX stock →Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 6,400 employees
TAK vs VRTX FAQ
Which is bigger, Takeda Pharmaceutical or Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) is larger, with a market capitalization of $128.16B compared with $58.68B for Takeda Pharmaceutical (TAK).
Which stock has performed better over the past year, TAK or VRTX?
TAK returned +27.04% over the past 12 months, compared with +23.24% for VRTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Takeda Pharmaceutical or Vertex Pharmaceuticals?
Takeda Pharmaceutical pays a dividend yielding 1088.73%, while Vertex Pharmaceuticals does not currently pay a regular dividend.
Are Takeda Pharmaceutical and Vertex Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.